newsfilter
← Latest News
PR Newswire·

Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women

SAN DIEGO, Oct. 11, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) announced today that the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea